Latest Innovation News

X2M Connect reports a 43% revenue decline in FY25 but improves gross margins and expands into the Middle East and renewable energy sectors, setting a positive outlook for FY26.

MoneyMe Limited posted a statutory net loss of $66.6 million for FY25, driven by accounting adjustments and credit loss provisions despite strong loan book growth and funding advances. The company is poised for growth with a new credit card launch and ongoing AI integration.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Raiz Invest Limited reported a robust FY25 with 15% revenue growth and a 147% jump in underlying EBITDA, driven by innovative products and AI-powered marketing. The company projects further earnings growth in FY26 amid expanding customer base and strategic partnerships.

RPM Automotive Group reported a mixed FY25 with a slight revenue decline but improved profitability and launched a tyre recycling initiative signaling a strategic shift.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

RPM Automotive Group reported a 5% revenue decline and an 8% drop in net profit from continuing operations for FY25, while launching a pioneering tyre recycling program aimed at sustainable growth.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.